Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Clinical trial NCT06084481 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06084481
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Pancreatic Ductal Adenocarcinoma Biliary Tract Cancers Esophageal Squamous Cell Carcinoma Triple Negative Breast Cancer Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Head and Neck Squamous-Cell Carcinoma Platinum Resistant High Grade Epithelial Ovarian Cancer

Start date: 2023-11-09
Primary completion: 2027-09-01
Enrollment: 302

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.